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Abstract
Background: Many administrative data sources are available to study the epidemiology of infectious diseases,
including Clostridium difficile infection (CDI), but few publications have compared CDI event rates across databases
using similar methodology. We used comparable methods with multiple administrative databases to compare the
incidence of CDI in older and younger persons in the United States.
Methods: We performed a retrospective study using three longitudinal data sources (Medicare, OptumInsight
LabRx, and Healthcare Cost and Utilization Project State Inpatient Database (SID)), and two hospital encounter-level
data sources (Nationwide Inpatient Sample (NIS) and Premier Perspective database) to identify CDI in adults aged
18 and older with calculation of CDI incidence rates/100,000 person-years of observation (pyo) and CDI
categorization (onset and association).
Results: The incidence of CDI ranged from 66/100,000 in persons under 65 years (LabRx), 383/100,000 in elderly
persons (SID), and 677/100,000 in elderly persons (Medicare). Ninety percent of CDI episodes in the LabRx
population were characterized as community-onset compared to 41 % in the Medicare population. The majority
of CDI episodes in the Medicare and LabRx databases were identified based on only a CDI diagnosis, whereas
almost ¾ of encounters coded for CDI in the Premier hospital data were confirmed with a positive test result plus
treatment with metronidazole or oral vancomycin. Using only the Medicare inpatient data to calculate encounter-level
CDI events resulted in 553 CDI events/100,000 persons, virtually the same as the encounter proportion calculated
using the NIS (544/100,000 persons).
Conclusions: We found that the incidence of CDI was 35 % higher in the Medicare data and fewer episodes were
attributed to hospital acquisition when all medical claims were used to identify CDI, compared to only inpatient
data lacking information on diagnosis and treatment in the outpatient setting. The incidence of CDI was 10-fold
lower and the proportion of community-onset CDI was much higher in the privately insured younger LabRx
population compared to the elderly Medicare population. The methods we developed to identify incident CDI
can be used by other investigators to study the incidence of other infectious diseases and adverse events using
large generalizable administrative datasets.
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Background
Clostridium difficile infection (CDI) incidence in the
United States has increased dramatically since 2000
[1, 2]. The number of discharges from non-federal,
acute care hospitals assigned the International Clas-
sification of Diseases, Ninth Revision, Clinical Modi-
fication (ICD-9-CM) diagnosis code for CDI (008.45)
increased by 2.7-fold between 2000 and 2012 using
data from the Healthcare Cost and Utilization Pro-
ject (HCUP) Nationwide Inpatient Sample (NIS) [3].
CDI was estimated to cause as many as 14,000
deaths in 2007 and an attributable mortality ranging
from 5.7 % in endemic settings to 16.7 % in severe
outbreaks since 2000 [2, 4–7].
Much research has focused on identifying specific risk
factors for CDI, but this might not be the best approach
to identify high risk populations. The results of risk fac-
tor studies have not always been consistent [8–15], with
potential reasons for discrepancies including differences
in patient populations, data availability, and/or study
definitions. These differences limit both the ability to
compare results across studies and the generalizability of
results, making it difficult to identify which populations
have the highest CDI burden and how to best target
CDI prevention practices.
Billing and claims data (referred to collectively as ad-
ministrative data) are increasingly used for health services
and outcomes research because of large population sizes,
generalizability of findings, and the ability to follow in-
dividuals across the spectrum of health care. Unfortu-
nately there is no single, comprehensive database in the
U.S. that can be used to identify all populations at risk
for CDI. In order to better understand the epidemi-
ology of CDI we applied common definitions to identify
and classify CDI from five large administrative data-
bases, the Medicare 5 % Sample, HCUP State Inpatient
Databases (SID) and the NIS, OptumInsight™ Retro-
spective Database (LabRx), and Premier Perspective, to
improve our understanding of the burden of CDI in the
U.S. from a population perspective.
Methods
The databases used for this study were anonymized;
some contained encrypted identifiers to link longitudinal
data within a person (“cohort” data), while the others
consisted of only unlinked hospital billing data. The hos-
pital billing databases (NIS, Premier) were analyzed at
the hospital discharge level. The cohort databases con-
taining a person-level identifier to track persons across
healthcare encounters (Medicare, LabRx, and SID) were
analyzed at both the person-level and hospital discharge-
level. For all cohort data hospitalizations with same-day
transfers to the same or a different hospital were aggre-
gated and treated as a single hospital stay, to avoid over-
counting long hospitalizations or direct transfers as dis-
tinct hospital visits. The Washington University Human
Research Protection Office and Geisel School of Medi-
cine at Dartmouth Committee for the Protection of
Human Subjects gave approval to conduct this research
with a waiver of informed consent.
Identification of CDI
Criteria used to identify CDI combined any of the
following:
1) ICD-9-CM diagnosis code for CDI (008.45) during
an inpatient hospital stay;
2) ICD-9-CM diagnosis code for CDI in an outpatient
encounter with specific restrictions (see Additional
file 1: Appendix);
3) Positive test result for C. difficile toxins or toxin
genes (LabRx); and
4) Non-topical metronidazole or oral vancomycin
therapy within ± 14 days of a CPT-4 code for a
C. difficile test or diagnosis code for CDI
(Medicare, LabRx, and Premier).
For person-level analyses, subsequent unique epi-
sodes of CDI were identified if the person met criteria
for CDI again after an 84 day period during which there
were no healthcare encounters meeting the CDI case
definition. We used a conservative definition for subse-
quent unique episodes of CDI to minimize misclassify-
ing carry-forward of the CDI diagnosis code or CDI
recurrence as a unique episode of CDI.
Inclusion/exclusion criteria
For Medicare and LabRx data, enrollment and complete
health insurance coverage for the year prior to the first
onset date of CDI was required. For Medicare age ≥
66 years at the time of CDI onset was required; for the
SID, NIS, and Premier all persons aged ≥ 18 years were
included. Individuals 65 and older were excluded from
the LabRx data since they represented only 7 % of the
privately insured population. For the cohort data CDI
episodes were excluded if the person had CDI within the
prior 84 days in order to identify new episodes of CDI in
2009.
Date of onset and determination of the location of onset
and attribution of CDI
The date of onset of CDI was defined as the first date
corresponding to a coded diagnosis of CDI. In the LabRx
data, if a CDI toxin test was performed, the date of the
first positive test was used as the date of CDI onset.
The location of onset and attribution for each CDI
episode was determined using an algorithm based on the
most recent SHEA/IDSA definitions [16–18]. CDI coded
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during a hospitalization was classified as community-
onset if: 1) CDI was the primary diagnosis; 2) the pri-
mary diagnosis was diarrhea, abdominal pain, or nausea
and CDI was coded in a secondary position; or 3) CDI
was coded in a secondary position and the hospital
length of stay was ≤ 3 days. If no further information was
available from outpatient or physician claims, CDI was
classified as hospital-onset if it was coded in a secondary
position and the hospital length of stay was > 3 days. If
the database did not contain a common person identifier,
no further categorization beyond community- or hospital-
onset was possible. If a common person identifier was
available and the CDI episode was community-onset, hos-
pitalizations and other healthcare facility exposures prior
to the CDI hospital admission were identified to classify
the episode (see Additional file 1: Appendix).
Analysis
The rate of CDI in a population group was defined as
the number of CDI episodes divided by the person-years
of observation (pyo, defined from 1/1/2009 up to the
next CDI event, death, or 12/31/2009, whichever came
first). For the SID the population of adults aged 18–64
and the elderly in the seven states was obtained from
the 2010 census (www.census.gov). Person-years in the
SID data were calculated taking into account death
(using the midpoint of the death discharge quarter to
define the date of death). SAS version 9.3 and SPSS 20.0
were used for data management and analysis.
Results
The demographic characteristics and number of hospi-
talizations and outpatient encounters in the different da-
tabases are shown in the Additional file 1: Appendix. In
the three longitudinal datasets approximately 0.2 % of
the initially identified hospitalizations coded for CDI
were excluded because the patient was previously identi-
fied with CDI within the prior 12 weeks. The criteria
used to identify CDI are shown in Table 1. In the Medi-
care data 23 % of inpatient CDI episodes were identified
by the CDI diagnosis code together with an outpatient
prescription for metronidazole or oral vancomycin
within 14 days after hospital discharge; when restricted
to patients with Part D coverage this corresponded to
40 % of inpatient CDI episodes (1303/3280). In the
Medicare data approximately 53 % of unique CDI in-
patient hospital episodes were identified by a secondary
diagnosis code during the hospitalization, consistent
with hospital-onset CDI, compared to 70 % in the SID,
and 23 % in the LabRx data. In the encounter-level
Table 1 CDI Episodes in 2009 according to the definition used to identify CDI
Definition Medicarea Lab/Rxa SIDa Premier NIS
Positive test + diagnosis + Rx N/A N/A – 4,623 (72.8) –
Diagnosis + Rx within 14 days after hospital discharge
or during hospitalization
1,303 (23.4) 1,088 (65.5) – 1,347 (21.2) –
Diagnosis + Positive test during hospitalization N/A N/A – 108 (1.7) –
Primary diagnosis 994 (17.8) 194 (11.7) 20,894 (30.5) 13 (0.02) 110,553 (32.8)
Diagnosis on admission 338 (6.1) N/A N/A 2 (< 0.01) N/A
Positive test only N/A N/A N/A 205 (3.2) N/A
Secondary diagnosis 2,941 (52.7) 379 (22.8) 47,546 (69.5) 52 (0.08) 226,012 (67.2)
Total Inpatient CDI 5,576 1,661 68,440 6,350 336,565
Positive test + Diagnosis + Rx within +/−14 days
of diagnosis or positive test date(s)
N/A 87 (2.7) – – –
Diagnosis on≥ 2 service dates + Rx within +/−14 days
of diagnosis date(s)
422 (10.4) 409 (12.6) – – –
Positive test + diagnosis within +/−14 days N/A 6 (0.2) – – –
Positive test + Rx within +/−14 days N/A 436 (13.4) – – –
Diagnosis + Rx + lab test within +/−14 days of the diagnosis
or lab test date(s)
133 (3.3) 148 (4.6) – – –
Diagnosis + Rx within +/−14 days 334 (8.2) 524 (16.1) – – –
Positive test only N/A 262 (8.1) – – –
Diagnosis only 3,162 (77.6) 1,251 (38.5) – – –
CDI test + Rx 25 (0.6) 129 (4.0) – – –
Total Outpatient CDI 4,076 3,252 – – –
aNumber of unique CDI episodes spaced at least 12 weeks apart
Rx = non-topical metronidazole or oral vancomycin therapy
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Premier data, 73 % of CDI hospitalizations were iden-
tified by a C. difficile laboratory test, diagnosis, plus
metronidazole or oral vancomycin therapy, and 21 %
were identified based on the CDI diagnosis code plus
treatment without a positive test result.
Approximately 42 % of the CDI episodes in the Medicare
data were first identified in the outpatient setting (Table 1).
Of these outpatient CDI episodes, 78 % were identified by
the CDI diagnosis code alone, and 21.8 % were identified
by the diagnosis code plus outpatient CDI prescription
(35 % for individuals with Part D coverage). Fifteen percent
(610/4076) of the persons identified with CDI outside of
the hospital were hospitalized within 14 days of CDI diag-
nosis; of these 60 % (364/610) were coded for CDI during
the inpatient hospitalization. In the LabRx data of younger
persons, 38.5 % of outpatient CDI episodes were identified
by the CDI diagnosis code only with no supporting labora-
tory or prescription evidence for infection. A total of
28.7 % of the outpatient CDI episodes in the LabRx data
were identified by a diagnosis code plus therapy, while
13.4 % of outpatient CDI episodes were identified by a
positive C. difficile test plus therapy within 14 days.
The categorization of CDI episodes by database is
shown in Table 2. Fifty-nine percent of CDI episodes
(5648/9652) were categorized as healthcare facility onset
(hospital or other facility) in the Medicare data, com-
pared to 68 % in the SID (46,739/68,440). Community-
onset healthcare facility-associated CDI made up 13 % of
the CDI episodes in Medicare, compared to 11.8 % in
the SID. Community-onset community-associated CDI
episodes included 22.6 % of episodes in Medicare vs.
13.9 % in the SID and 35.2 % in the Premier data. Only
22.4 % (1102/4913) of the CDI episodes in the LabRx
data were healthcare facility associated (excluding inde-
terminate association), while 68.4 % of episodes were
categorized as community-onset community-associated.
The number of persons with one or more than one
unique episode of CDI in the longitudinal datasets is
shown in Table 3 and the cumulative incidence of
CDI in Table 4. 2.6 % of persons in the Medicare and
5.0 % of persons in the LabRx data had > 1 unique
episode of CDI spaced at least 12 weeks apart in
2009. The rate of CDI in the Medicare data was 677/
100,000 pyo, while the rate was 43 % lower (383) in
the SID. The rate of CDI in the younger adult popu-
lation in the SID was ten-fold lower (37.5) than the
rate in the elderly SID population, while the rate of
CDI in the LabRx data including outpatient CDI was
1.8-fold higher than in the SID younger population.
The rate of hospital onset CDI per 10,000 patient
days was higher in the SID for elderly persons (15.9) com-
pared to the Medicare data (9.8), lower in the SID and
Premier data for younger adults, and lowest (1.1) in the
LabRx data.
To determine the impact of including outpatient
medical claims and linkage within a person on CDI
incidence, we compared the cumulative incidence,
categorization of episodes, and attribution of CDI in
the Medicare data when complete claims were used vs.
only inpatient facility claims, with and without linkage
within a person. When only the inpatient facility
claims were used (analogous to the SID), the total
number of CDI episodes was reduced to 6276 and the
cumulative incidence of CDI decreased to 440/100,000
pyo. In addition, the number of hospital-onset cases
and the rate of hospital-onset CDI increased while
community-associated CDI decreased over two-fold
(Table 5). When the person-level linkage in the in-
patient Medicare data was removed (analogous to the
Table 2 Categorization of CDI episodes in the different databases
Medicare Lab/Rx SID Premiera NIS
Hospital-Onset 3,223 (33.4) 449 (9.1) 46,347 (67.7) 3,984 (64.8) 211,344 (62.8)
Other Healthcare-Facility Onset 2,425 (25.1) 54 (1.1) 392 (5.7) – –
Community-Onset Hospital-associated 1,258 (13.0) 599 (12.2) 8,048 (11.8) – –
Community-Onset Indeterminate-association 561 (5.8) 451 (9.2) 4,139 (6.0) – –
Community-Onset Community-associated 2,185 (22.6) 3,360 (68.4) 9,514 (13.9) – –
Community-Onset Unknown associationb – – – 2,161 (35.2) 125,221 (37.2)
aThe number of CDI events is reduced by 205 due to diagnosis of CDI by a positive test result only
bEpisodes in the Premier and NIS encounter-level databases were classified as community-onset unknown association since it was not possible to determine prior
health care exposures due to lack of a person-level identifier
Table 3 Number of persons with multiple incident CDI episodes
(no other CDI diagnosis within 12 weeks)
Medicare LabRx SID
Size of the cohort 1,465,927 7,255,708 5,575,935
No CDI 1,456,526 7,251,046 5,508,903
Only one CDI 9,155 (97.4)a 4,429 (95.0) 65,549 (97.9)
2 CDI 241 (2.6) 215 (4.6) 1,403 (2.1)
> 2 CDI 5 (0.05) 18 (0.4) 28 (0.04)
aPercentages refer to percentage of persons with CDI
Olsen et al. BMC Infectious Diseases  (2016) 16:177 Page 4 of 8
NIS), the number of CDI episodes increased by almost
30 % compared to the linked inpatient Medicare data
(8108 vs. 6276), because of the inability to exclude
hospitalizations coded for CDI in the prior 12 weeks.
The number of CDI events/100,000 hospitalizations
was 553/100,000 hospitalizations using the unlinked
data. When the 2009 NIS data was restricted to hospi-
talizations in elderly persons aged 65 years and older,
the CDI hospitalization proportion was 544 CDI
visits/100,000 hospitalizations.
Discussion
We used five types of billing or claims data to define the
burden of CDI in U.S. adults in 2009. To our knowledge
this is the first study to compare the burden of CDI
from a population perspective in different administrative
Table 4 Burden of CDI in the elderly in 2009 in the different databases, including all episodes of CDI
Adults < 65 Years Lab/Rx SID Premier NIS
Rate of CDI/100,000 person-years 66.0 37.5a N/A N/A
Rate of hospital onset CDI/10,000 pt. days 1.1 5.7 5.4 6.9
Prevalence of CDI at admission/1,000 hospitalizations N/A 1.5 1.9 2.0
Rate of healthcare facility-associated CDI/10,000 pt. days 2.1 N/A N/A N/A
Elderly Medicare SID Premier NIS
Rate of CDI/100,000 person-years 677 383b N/A N/A
Rate of hospital onset CDI/10,000 pt. days 9.8 15.9 11.6 15.5
Prevalence of CDI at admission/1,000 hospitalizations 5.4 4.7 6.3 6.2
Rate of healthcare facility-associated CDI/10,000 pt. days 12.5 N/A N/A N/A
arate/100,000 persons in 7 states aged 18–64 years
brate/100,000 persons in 7 states aged > = 65 years
Table 5 Comparison of the number of CDI episodes in 2009 in the Medicare data according to the extent of information used to
identify CDI
Source of information from medicare files
Type of CDI Definition of CDI Complete inpatient + outpatient Inpatient only
(comparable to SID)
Inpatient-unlinked
(comparable to NIS)
# hospital stays – 488,344 488,344 522,921
Total Inpatient CDI episodes – 5,576 6,276 8,108
Inpatient CDI Episodes Primary discharge diagnosis) 1,464 1,690 2,084
Admission diagnosis 487 584 824
Secondary discharge diagnosis 3,625 4,002 5,200
Outpatient CDI episodes – 4,076 N/A N/A
Total CDI episodes – 9,652 6,276 8,108
Categorization of CDI Episodes (% of episodes)
Hospital-Onset 3,223 (33.4) 3,765 (60.0) 4,769 (58.8)
Other Healthcare Facility-Onset 2,425 (25.1) N/A N/A
Community-Onset Healthcare Facility–associated 1,258 (13.0) 938 (14.9) N/A
Community-associated CDI 2,185 (22.6) 1,032 (16.4) 3,339 (41.2)
Indeterminate 561 (5.8) 541 (8.6) N/A
Rate of CDI Episodes
Rate of CDI/100,000 person-years 677 440 553a
Rate of hospital onset CDI/10,000 pt. days 9.8 11.4 14.1
Prevalence of CDI at admission/1,000 hospitalizations 5.4 5.3 6.5
Rate of healthcare facility-associated CDI/10,000 pt. days 12.5 14.2 14.1
aper 100,000 population aged 65 and older from the 2010 census
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databases using standardized methods to identify and
classify CDI. We used all available information to iden-
tify CDI, including outpatient prescription claims for
metronidazole and vancomycin in the Medicare (Part D)
and LabRx data, inpatient treatment in Premier, and out-
patient C. difficile test results in LabRx.
Not surprisingly, we found a higher cumulative inci-
dence of CDI in the databases that contained inpatient
and outpatient data compared to only inpatient billing
data, similar to what was reported recently using Kaiser
Permanente data [19]. The number of CDI episodes per
100,000 elderly persons was almost 1.8-fold higher in
the Medicare data compared to the inpatient only
longitudinal-SID. However, when only inpatient data
were used to identify CDI in the Medicare population
and the analysis was conducted at the person-level, the
cumulative incidence of CDI was very close to that cal-
culated in the SID (440 vs. 383/100,000 pyo). The 54 %
increase in the cumulative incidence using complete
(677) vs. inpatient-only Medicare data (440) emphasizes
the importance of using complete data from inpatient
and outpatient settings to calculate CDI incidence. In
addition, when we treated the inpatient Medicare data as
encounter-level (i.e., hospitalizations as unique encoun-
ters), the number of CDI events/100,000 hospitalizations
was remarkably similar to the 544 /100,000 hospitaliza-
tions in elderly persons in the 2009 NIS.
More CDI cases were identified as hospital-onset in
the datasets with only inpatient facility data, resulting in
a higher apparent hospital-onset CDI incidence. The rate
of hospital-onset CDI increased in the Medicare data to
11.4 cases/10,000 patient days when analysis was re-
stricted to only inpatient facility claims, and this rate in-
creased further when the linkage within a patient was
ignored (14.1 cases/10,000 patient days). This suggests
that analysis of encounter-level data, such as the NIS,
may result in over-estimation of CDI hospital rates by as
much as 25 % due to continued coding in subsequent
hospitalizations that are part of the same CDI episode,
and that caution should be used when using these data
for surveillance purposes.
In analysis of complete Medicare claims, 33 % of the
CDI events were categorized as hospital-onset, whereas
in the analyses using only inpatient Medicare facility
data, approximately 60 % of the CDI events were catego-
rized as hospital-onset, suggesting that hospital-onset
cases will be over-estimated by almost two-fold when
only inpatient claims or billing data are used. These re-
sults are consistent with previous reports of the over-
attribution of hospital-onset CDI [20, 21] and the over-
estimation of CDI cases identified by the ICD-9-CM
diagnosis code compared to positive C. difficile toxin
assay from facility billing data [20, 22–25]. More
hospital-onset cases were identified in the HCUP and
Premier data, likely due to misclassification of CDI with
onset in the community.
The addition of laboratory results in the LabRx data
suggests that 20 % of CDI episodes may be missed when
analyzing data without C. difficile test results. Identifica-
tion of fecal transplant in administrative data via CPT-4
and HCPCS codes (available beginning 2013) may aid in
the identification of CDI in future, particularly in com-
bination with a positive C. difficile test result. Interest-
ingly, approximately three-quarters of the outpatient
CDI episodes in the LabRx data were not supported by a
positive test result, with 38 % identified on the basis of a
CDI diagnosis alone. The percentage of outpatient CDI
diagnoses without confirmation by a positive C. difficile
laboratory test was very similar in our previous study
using Veterans Administration data, in which only 32 %
of the total outpatient CDI cases had a C. difficile test
result [26]. Further studies to validate the use of the
ICD-9-CM diagnosis code for CDI in the outpatient set-
ting in the absence of positive C. difficile test results are
warranted to determine the accuracy of coding outside
of the hospital.
In the Medicare data 23 % of CDI episodes first diag-
nosed during an inpatient hospital stay were linked to a
filled outpatient prescription consistent with CDI treat-
ment within 2 weeks after hospital discharge. Since
47.5 % of the Medicare patients had Part D coverage,
this would suggest that almost half of elderly persons
diagnosed with CDI during an inpatient hospitalization
continue CDI treatment after leaving the hospital. In
the LabRx data almost two-thirds of episodes identified
during a hospitalization were linked to outpatient CDI
treatment. We identified temporally related treatment
of outpatient CDI in at most one-half of persons with
prescription drug coverage in the Medicare (46 %) and
LabRx (49 %) data. In contrast, in the Premier data con-
taining inpatient medications, 73 % of inpatient CDI epi-
sodes had evidence of treatment during the hospitalization.
Despite lack of documentation of treatment for many CDI
cases, particularly in the Medicare data, the overall in-
cidence of CDI in the elderly of 677/100,00 pyo is re-
markably similar to the incidence of 628/1000,000
elderly persons reported by the Centers for Disease
Control and Prevention’s Emerging Infections Program
(EIP) for 2011 [2].
Lessa reported that 53 % of CDI events (159,700
community-associated + 81,300 community-onset, health
care facility associated) in persons of all ages were
community-onset using the EIP data [2], similar to the
41.4 % community-onset CDI episodes we identified in
the Medicare data. In the recent publication using Kaiser
Permanente data, 76 % of the CDI events were
community-onset, with a total of 40 % characterized as
community-onset community-associated [19]. This is
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lower than our finding that almost 90 % of the CDI
events in the LabRx data from younger persons had on-
set in the community, with 68 % characterized as
community-onset community associated CDI. The vary-
ing proportions of CDI with onset outside of the hospital
in the Medicare and LabRx data compared to the EIP
data may be related to differences in age of the popula-
tions. In the EIP data, 44 % of persons with CDI were
< 65 years of age, and the proportion of CDI that is
community-associated CDI is higher in younger popu-
lations [27]. Consistent with our current study, 52 % of
laboratory-identified CDI during inpatient hospitaliza-
tions in the EIP were present at admission to the hos-
pital [28].
Conclusions
The similarities between our findings concerning the in-
cidence and site of onset of CDI from several different
administrative databases with recent EIP results validate
use of these administrative databases to identify popula-
tions at risk for CDI. We determined how results may
be skewed when important information is missing, such
as outpatient data and encrypted identifiers, and the ad-
vantages of using complete claims data allowing for sub-
stantiation of the CDI diagnosis using laboratory claims
for CDI testing, pharmacy claims for CDI treatment, and
other diagnoses consistent with CDI (e.g., diarrhea). Al-
though there are limitations to use of administrative
data, these databases offer the opportunity to analyze
CDI from a population perspective, including data from
many different hospitals and from other healthcare facil-
ities. These databases can provide more complete infor-
mation on the epidemiology of CDI and enrich our
understanding of the impact of CDI on young and older
persons in the U.S. In addition, the methods we devel-
oped to extract comparable information can be used to
determine the incidence of other infectious diseases
(e.g., MRSA, septicemia) and adverse events (e.g., deep
venous thrombosis) in varying populations using a com-
bination of different administrative databases.
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